Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MY006 (Mengyang Pharmaceutical)
- Development stage
- Preclinical
- Lead developer
- Mabylon
- Modality
- Small Molecules
01
Overview
MY006 is a small molecule, classified as a Class 1 Chemical Drug, being developed by Monyan Pharmaceutical for oncology supportive care. It is designed to address multiple complications associated with cancer and its treatment, including liver protection, improvement of heart function, increasing platelet counts, and managing cancer-related fatigue. As of 2024, the drug is in the IND-enabling stage, with clinical trial applications planned for that year.
02
Targets
Ara h 2
Beyond the preview
Go deeper on MY006 (Mengyang Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MY006 (Mengyang Pharmaceutical).